Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a ...

Adibelivir is a next generation helicase-primase inhibitor. The oral formulation is advancing toward Phase 2 development for genital herpes, while the parenteral formulation is dedicated exclusively ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the most undervalued blue chip stocks to buy now.

Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a ...

Foster City: Gilead Sciences and Assembly Biosciences have announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a 2020 licensing agreement. The breakup was initiated by GSK on Dec. 4, Ideaya ...

In the mid-1990s, researchers identified the viral helicase–primase enzyme complex as a target for a potential anti-herpes simplex virus (HSV) therapy. Three decades later, the first promising ...